PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $7.0m | Post IPO Convertible |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
PharmaCyte Biotech is a clinical-stage biotechnology company dedicated to developing and commercializing innovative treatments for cancer and diabetes. The company operates in the healthcare and pharmaceutical markets, focusing on patients with hard-to-treat diseases. PharmaCyte Biotech's primary clients include healthcare providers, hospitals, and research institutions that require advanced therapeutic solutions for their patients.
The company's core technology is its proprietary Live Cell Encapsulation platform. This unique and patented technology involves encapsulating live cells in a cellulose-based material, which can then be used to deliver targeted treatments directly to the affected areas in the body. This approach aims to increase survival time and improve the quality of life for patients by treating symptoms more effectively.
PharmaCyte Biotech generates revenue through the development and eventual commercialization of its novel therapies. As a clinical-stage company, it is currently focused on research and development (R&D) activities, conducting clinical trials, and obtaining regulatory approvals. Once these therapies are approved, the company plans to license its technology to pharmaceutical companies or directly market its treatments to healthcare providers.
The company has successfully completed several key milestones, including container closure integrity tests and three-month stability studies, which are crucial steps in ensuring the safety and efficacy of its treatments. These achievements demonstrate PharmaCyte Biotech's commitment to advancing its therapies through rigorous testing and validation processes.
In summary, PharmaCyte Biotech is a pioneering company in the biotechnology sector, leveraging its Live Cell Encapsulation technology to develop targeted treatments for cancer and diabetes. By focusing on hard-to-treat diseases, the company aims to make a significant impact on patient outcomes and the broader healthcare market.
Keywords: biotechnology, cancer treatment, diabetes treatment, Live Cell Encapsulation, clinical trials, healthcare, pharmaceutical, R&D, innovative therapies, patient-focused.
